CN113329790A - 激酶抑制剂的结晶形式和盐形式 - Google Patents

激酶抑制剂的结晶形式和盐形式 Download PDF

Info

Publication number
CN113329790A
CN113329790A CN201980090041.5A CN201980090041A CN113329790A CN 113329790 A CN113329790 A CN 113329790A CN 201980090041 A CN201980090041 A CN 201980090041A CN 113329790 A CN113329790 A CN 113329790A
Authority
CN
China
Prior art keywords
compound
peaks
xrpd pattern
scale
crystalline solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980090041.5A
Other languages
English (en)
Chinese (zh)
Inventor
F·德莫林
K·沙
S·谢克亚
P·王
C·S·约翰逊
M·J·贝威尔
S·D·帕伦特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CN113329790A publication Critical patent/CN113329790A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980090041.5A 2018-12-13 2019-12-12 激酶抑制剂的结晶形式和盐形式 Pending CN113329790A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862779430P 2018-12-13 2018-12-13
US62/779,430 2018-12-13
US201962856469P 2019-06-03 2019-06-03
US62/856,469 2019-06-03
PCT/US2019/065972 WO2020123800A1 (en) 2018-12-13 2019-12-12 Crystalline forms and salt forms of a kinase inhibitor

Publications (1)

Publication Number Publication Date
CN113329790A true CN113329790A (zh) 2021-08-31

Family

ID=69160358

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980090041.5A Pending CN113329790A (zh) 2018-12-13 2019-12-12 激酶抑制剂的结晶形式和盐形式

Country Status (33)

Country Link
US (2) US12017995B2 (cg-RX-API-DMAC7.html)
EP (2) EP4631505A3 (cg-RX-API-DMAC7.html)
JP (3) JP7509779B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250103803A (cg-RX-API-DMAC7.html)
CN (1) CN113329790A (cg-RX-API-DMAC7.html)
AU (2) AU2019395419B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011333A2 (cg-RX-API-DMAC7.html)
CA (1) CA3122840A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001537A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007613A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210375A (cg-RX-API-DMAC7.html)
DK (1) DK3894012T3 (cg-RX-API-DMAC7.html)
ES (1) ES3052838T3 (cg-RX-API-DMAC7.html)
FI (1) FI3894012T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20247596B (cg-RX-API-DMAC7.html)
HR (1) HRP20251122T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072868T2 (cg-RX-API-DMAC7.html)
IL (2) IL283860B2 (cg-RX-API-DMAC7.html)
LT (1) LT3894012T (cg-RX-API-DMAC7.html)
MA (1) MA54458B1 (cg-RX-API-DMAC7.html)
MD (1) MD3894012T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021006951A (cg-RX-API-DMAC7.html)
PE (1) PE20211757A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551356A1 (cg-RX-API-DMAC7.html)
PL (1) PL3894012T4 (cg-RX-API-DMAC7.html)
PT (1) PT3894012T (cg-RX-API-DMAC7.html)
RS (1) RS67216B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105949RA (cg-RX-API-DMAC7.html)
SI (1) SI3894012T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500346T1 (cg-RX-API-DMAC7.html)
TW (2) TWI913821B (cg-RX-API-DMAC7.html)
WO (1) WO2020123800A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103844B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115461328A (zh) * 2020-04-30 2022-12-09 埃克塞里艾克西斯公司 用于制备激酶抑制剂的方法
WO2025001997A1 (zh) * 2023-06-28 2025-01-02 中国人民解放军军事科学院军事医学研究院 喹啉类化合物及其制备方法、药物组合物及医药用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
KR102826380B1 (ko) * 2019-06-03 2025-06-26 엑셀리시스, 인코포레이티드 카이네이스 저해제의 결정질 염 형태
PH12023550160A1 (en) 2020-07-31 2023-09-18 Exelixis Inc Combinations for the Treatment of Cancer
IL302485A (en) * 2020-11-05 2023-06-01 Exelixis Inc Kinase inhibitor pharmaceutical preparations
CN112650176B (zh) * 2020-12-22 2022-08-30 天能化工有限公司 一种盐酸解析开停车工序的dcs控制方法
AR127561A1 (es) * 2021-11-03 2024-02-07 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas
AU2022420610A1 (en) 2021-12-22 2024-06-27 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
JP4667537B2 (ja) 2008-04-10 2011-04-13 大鵬薬品工業株式会社 アシルチオウレア化合物又はその塩、及びその用途
AU2009303602B2 (en) 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
EA032757B1 (ru) 2014-02-14 2019-07-31 Экселиксис, Инк. Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
CN104817497B (zh) 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
MX2019012505A (es) 2017-05-26 2019-12-19 Exelixis Inc Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
HRP20251184T1 (hr) 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
KR102826380B1 (ko) * 2019-06-03 2025-06-26 엑셀리시스, 인코포레이티드 카이네이스 저해제의 결정질 염 형태

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115461328A (zh) * 2020-04-30 2022-12-09 埃克塞里艾克西斯公司 用于制备激酶抑制剂的方法
CN115461328B (zh) * 2020-04-30 2025-11-07 埃克塞里艾克西斯公司 用于制备激酶抑制剂的方法
WO2025001997A1 (zh) * 2023-06-28 2025-01-02 中国人民解放军军事科学院军事医学研究院 喹啉类化合物及其制备方法、药物组合物及医药用途

Also Published As

Publication number Publication date
JP2024038167A (ja) 2024-03-19
IL283860B2 (en) 2025-10-01
IL320433A (en) 2025-06-01
US20230029213A1 (en) 2023-01-26
HRP20251122T1 (hr) 2025-11-21
LT3894012T (lt) 2025-10-10
MX2021006951A (es) 2021-07-15
IL283860A (en) 2021-07-29
EP4631505A2 (en) 2025-10-15
AU2019395419A1 (en) 2021-07-01
JP7509779B2 (ja) 2024-07-02
GEP20247596B (en) 2024-02-26
PL3894012T3 (pl) 2026-01-05
KR20250103803A (ko) 2025-07-07
JP2026031599A (ja) 2026-02-24
EP4631505A3 (en) 2025-12-10
ZA202103844B (en) 2024-11-27
JP7783870B2 (ja) 2025-12-10
TW202039440A (zh) 2020-11-01
WO2020123800A1 (en) 2020-06-18
JP2022512399A (ja) 2022-02-03
KR20210102381A (ko) 2021-08-19
PL3894012T4 (pl) 2026-01-05
HUE072868T2 (hu) 2025-12-28
PH12021551356A1 (en) 2021-12-06
CO2021007613A2 (es) 2021-06-21
MA54458B1 (fr) 2025-09-30
RS67216B1 (sr) 2025-10-31
CL2021001537A1 (es) 2022-02-04
ES3052838T3 (en) 2026-01-15
CA3122840A1 (en) 2020-06-18
SI3894012T1 (sl) 2025-10-30
AU2025234277A1 (en) 2025-10-16
MA54458A (fr) 2021-10-20
SG11202105949RA (en) 2021-07-29
TWI913821B (zh) 2026-02-01
KR102828472B1 (ko) 2025-07-03
DK3894012T3 (da) 2025-09-15
PE20211757A1 (es) 2021-09-07
TWI852963B (zh) 2024-08-21
AU2019395419B2 (en) 2025-06-26
BR112021011333A2 (pt) 2021-08-31
MD3894012T2 (ro) 2025-11-30
US12679809B2 (en) 2026-07-14
EP3894012B1 (en) 2025-06-18
EP3894012A1 (en) 2021-10-20
TW202519513A (zh) 2025-05-16
SMT202500346T1 (it) 2025-11-10
CR20210375A (es) 2021-08-18
PT3894012T (pt) 2025-09-25
FI3894012T3 (fi) 2025-09-18
US12017995B2 (en) 2024-06-25
US20240300897A1 (en) 2024-09-12
IL283860B1 (en) 2025-06-01

Similar Documents

Publication Publication Date Title
JP7783870B2 (ja) キナーゼ阻害剤の結晶性形態及び塩形態
CN113939503B (zh) 激酶抑制剂的结晶盐形式
US20250368606A1 (en) Crystalline forms and salt forms of a kinase inhibitor
HK40060502A (en) Crystalline forms and salt forms of a kinase inhibitor
HK40067664A (en) Crystalline salt forms of a kinase inhibitor
HK40067664B (en) Crystalline salt forms of a kinase inhibitor
HK40061293A (en) Crystalline forms and salt forms of a kinase inhibitor
HK40061293B (en) Crystalline forms and salt forms of a kinase inhibitor
BR122025022768A2 (pt) Formas cristalinas, sais de ácido clorídrico e ácido fosfórico cristalinos, composição farmacêutica e usos relacionados
EA044424B1 (ru) Кристаллические формы и солевые формы ингибитора киназы
EA048718B1 (ru) Кристаллические солевые формы ингибитора киназы

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40060502

Country of ref document: HK